



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

1,3-Dimethyluracil

Cat. No.:	HY-W008343
CAS No.:	874-14-6
Molecular Formula:	C ₆ H ₈ N ₂ O ₂
Molecular Weight:	140.14
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (178.39 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		7.1357 mL	35.6786 mL	71.3572 mL
		5 mM		1.4271 mL	7.1357 mL	14.2714 mL
		10 mM		0.7136 mL	3.5679 mL	7.1357 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (17.84 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (17.84 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (17.84 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with K _i of 316.2 μM and 166.4 μM, respectively ^{[1][2]} .
-------------	---

REFERENCES

-
- [1]. Stoessel D, et al. Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. *Front Aging Neurosci.* 2018 Mar 5;10:51.
- [2]. Güney M, et al. Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives. *Bioorg Med Chem Lett.* 2015 Aug 15;25(16):3261-3.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA